Generic Name and Formulations:
Hexaminolevulinate HCl 100mg/vial; pwd for intravesical administration after reconstitution.
Indications for CYSVIEW:
For use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy. Use with Karl Storz D-Light C Photodynamic Diagnostic system to perform cystoscopy with the blue light setting (Mode 2) as an adjunct to the white light setting (Mode 1).
See literature. Instill 50mL into emptied bladder via a urinary catheter. Retain in bladder for 1 hour before evacuating and performing cystoscopic examination. First perform complete cystoscopic exam of entire bladder under white light, then repeat exam under blue light.
Porphyria. Gross hematuria. BCG immunotherapy or intravesical chemotherapy within the past 90 days.
Not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer or for repetitive use. Do not perform cystoscopy with blue light alone as malignant lesions can be missed unless the bladder is initially examined under white light. Presence of urine or blood may interfere with detection of tissue fluorescence. Pregnancy (Cat.C). Nursing mothers.
Optical imaging agent.
Bladder spasm, dysuria, hematuria, bladder pain, procedural pain, urinary retention, headache; anaphylaxis.
Kit—1 (vial + diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations